Biologics Safety Testing Market Anticipated To Value US$ 4.36 Billion By 2022

Global Market for Biologics Safety Testing Poised to Reach US$ 4.36 Bn value by 2022-end
Quality control measures for drug development are of utmost importance as inadvertent presence of
unknown pharmaceutical ingredients can further complicate health conditions of the patients.
Government authorities are closely watching over pharmaceutical companies and regulating their
drug manufacturing processes by compelling them to undertake safety tests. Large and complex
molecules such as biologics, which are produced from genes of living organisms through advanced
DNA technologies, are also being tested for their safety in biopharmaceutical production.
Biotechnological companies and pharmaceutical manufacturers continue to give high regards for
biologics safety testing products and services. The efficacy of biologics safety testing ensures that
tested medicine and drugs are not containing any extra ingredient, thereby preventing patients from
experiencing adverse reactions upon intake. A recently published report by Persistence Market
Research projects that the global market for biologics safety testing will soar at a robust CAGR of
8.8% over the forecast period, 2017-2022. The report anticipates that approx. US$ 4.36 Bn worth of
biologics safety testing products & services will be utilized globally by the end of 2022.
Request to view table of content @
According to the report, North America will remain at the forefront of global expansion of biologics
safety testing market. Throughout the forecast period, North America is anticipated to remain the
largest market for biologics safety testing products & services. Key drug regulatory bodies such as
the FDA are based in North America. Moreover, the overall healthcare infrastructure in the US and
Canada is robust, and exhibits a high uptake for new and improved safety tests on biologics.
The biologics safety testing market in Europe is also expected to witness impressive growth. Global
leaders in biopharmaceutical production are expanding their presence in European countries such as
Germany and the UK. Moreover, the European region continues to showcase a scientifically- and
technologically-advanced healthcare marketplace for biologics safety testing.
A sample of this report is available upon request @
Likewise, Japan’s biologics safety testing market is also anticipated to incur rapid growth at a
CAGR of 9.3%. Meanwhile the Asia-Pacific excluding Japan (APEJ) region is anticipated to
witness stellar growth, particularly with respect to manufacturing of biologics safety testing
products. Low wages and favorable industrial regulations are expected to bolster the manufacturing
of biologics safety testing products in the APEJ region. Between 2017 and 2022, the APEJ biologics
safety testing market is estimated to create over US$ 270 Mn in absolute dollar opportunity.
Wuxi Apptec, Lonza Group Ltd., Toxikon Corporation, BioMerieux SA, Pace Analytical Services
Inc., Thermo Fisher Scientific Inc., Genscript Biotech Corp., Eurofins Scientific Se, SGS S.A.,
Sigma-Aldrich Corporation (Merck KGaA), and Charles River Laboratories International, Inc. are
profiled as key players in the global market for biologics safety testing. These companies are
anticipated to remain active in the expansion of global biologics safety testing market through 2022.
Browse Complete Report @
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research
model is a unique collaboration of data analytics and market research methodology to
help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a
multi-disciplinary approach. At PMR, we unite various data streams from multidimensional sources. By deploying real-time data collection, big data, and customer
experience analytics, we deliver business intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized
solutions to cater to client-specific needs, and consulting services to offer more value
addition. Our next-generation research approach for exploring emerging technologies
has allowed us to solve the most complex problems of clients. We do not follow a
reactive approach, but a pro-active one. Expert analysts at PMR keep a tab on nextgeneration technologies in their R&D phase and provide the latest insights into these
technologies when they are being commercialized. Our ground-breaking approach
allows us to deliver market solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies to
fast-growing startups. PMR’s collaborative environment is committed to building
industry-specific solutions by transforming data from multiple streams into a strategic
Contact Us:
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
Tel: +1-646-568-7751
Email: [email protected]
[email protected]